AGRICULTURAL AND FOOD CHEMISTRY

Design, Synthesis, and Pesticidal Activities of Pyrimidin-4-amine Derivatives Bearing a 5-(Trifluoromethyl)-1,2,4-oxadiazole Moiety

Xing-Hai Liu,* Yong-Hui Wen, Long Cheng, Tian-Ming Xu, and Ning-Jie Wu*

Cite This: J. Agric. F	ood Chem. 2021, 69, 6968–6980	Read Online	
ACCESS	III Metrics & More	Article Recommendations	

ABSTRACT: It is important to discover new pesticides with new modes of action because of the increasing evolution of pesticide resistance. In this study, a series of novel pyrimidin-4-amine derivatives containing a 5-(trifluoromethyl)-1,2,4-oxadiazole moiety were designed and synthesized. Their structures were confirmed by ¹H NMR, ¹³C NMR, and HRMS. Bioassays indicated that the 29 compounds synthesized possessed excellent insecticidal activity against *Mythimna separata, Aphis medicagini,* and *Tetranychus cinnabarinus* and fungicidal activity against *Pseudoperonospora cubensis*. Among these pyrimidin-4-amine compounds, 5-chloro-*N*-(2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)-6-(1-fluoroethyl) pyrimidin-4-amine (U7) and 5-bromo-*N*-(2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)-6-(1-fluoroethyl) pyrimidin-4-amine (U8) had broad-spectrum insecticidal and fungicidal activity. The LC₅₀ values were 3.57 ± 0.42, 4.22 ± 0.47, and 3.14 ± 0.73 mg/L for U7, U8, and flufenerim against *M. separata*, respectively. The EC₅₀ values were 24.94 ± 2.13, 30.79 ± 2.21, and 3.18 ± 0.21 mg/L for U7, U8, and azoxystrobin against *P. cubensis*, respectively. The AChE enzymatic activity testing revealed that the enzyme activities of compounds U7, U8, and flufenerim with the AChE model demonstrated the opposite docking mode between compound U7 or U8 and positive control flufenerim in the active site of AChE. The structure–activity relationships are also discussed. This work provided excellent pesticide for further optimization. Density functional theory analysis can potentially be used to design more active compounds.

KEYWORDS: pyrimidin-4-amine derivatives, synthesis, fungicidal, insecticidal, SAR

INTRODUCTION

Synthetic pesticides have been relied on in agriculture for pest management for 75 years, and resistance to them is evolving rapidly. Therefore, it is urgent to develop new pesticides to which both nontarget site and target-site resistance have not evolved as well as pesticides with new mechanisms of action.

Pyrimidines are important members of nitrogen-containing heterocycles in natural products, such as uracil, thymine, cytosine, caffeine, theophylline, variolin B, vitamin B1, and heteromine. Among them, cytosine, variolin B, vitamin B1, tingitamine, and heteromine contain a pyrimidinamine moiety (Figure 1). Currently, synthetic pyrimidinamine derivatives possess efficient, broad-spectrum, and diverse activities, such as antitumor,¹ fungicidal,² insecticidal,³ acaricidal,⁴ antioxidant,⁵ anti-HIV,6 and other biological activities. Due to the high biological activity of 4-substituted pyrimidinamine derivatives, they have been a focus of pesticide discovery. For example, Cuccia et al.⁷ reported a series of 4-position pyrimidinamine compounds that possessed good insecticidal activity against spider mites at 100 mg/L. Liu's group⁸ reported some new 4position pyrimidinamine compounds with activity against cucumber downy mildew using an intermediate derivatization method. Another example, the pyrimidinamine-type insecticides pyrimedifen and flufenerim were discovered by Ube Industries (Figure 1). It is reported that flufenerim targets AChE.⁹ These properties indicate that flufenerim could be a promising template for the discovery of new insecticide candidates.

1,2,4-Oxadiazole is a five-membered heterocycle containing O and N atoms, which has various biological activities, such as insecticidal,^{10,11} anticancer,^{12,13} fungicidal,¹⁴ anti-inflammatory,¹⁵ antibactericidal,¹⁶ antiproliferative,¹⁷ and antimalarial.¹⁸ In 2015, BASF^{19,20} reported 5-(trifluoromethyl)-1,2,4-oxadiazole compounds that possessed excellent fungicidal activity. Subsequently, some patents^{21–26} about fungicidal, herbicidal, or insecticidal 5-(trifluoromethyl)-1,2,4-oxadiazole compounds were filed by BASF, Syngenta, Sumitomo, Bayer, and others.

In our previous work, some 4-substituted pyrimidinamines^{3,27-29} with good insecticidal activity were designed and synthesized. In this paper, in order to discover new pyrimidinamine compounds, the insecticide flufenerim was selected as a template molecule. The amino group of the pyrimidine ring was linked by a 4-(5-(trifluoromethyl)-1,2,4oxadiazol-3-yl)benzyl group, the 5-position of pyrimidine was replaced by another halogen, and 1-fluoroethyl was replaced with an isopropyl group. Some of the synthetic pyrimidinamine

Received:January 13, 2021Revised:May 24, 2021Accepted:June 9, 2021Published:June 17, 2021





pubs.acs.org/JAFC



Figure 1. Some pyrimidinamine natural products and commercial pesticides.



Figure 2. Design strategy for new pyrimidinamine compounds.

Scheme 1. Synthesis of Key Pyrimidine Intermediates d1-d8



derivatives exhibited good insecticidal and fungicidal activity. Their mode of action was also studied. The design strategy in this paper is shown in Figure 2.

MATERIALS AND METHODS

Instruments. Melting points were determined using an X-4 apparatus, and the temperature was uncorrected. ¹H NMR and ¹³C NMR spectra were measured on a Bruker 600 MHz instrument using TMS as an internal standard and CDCl₃ as the solvent. High-resolution mass spectra (HRMS) were recorded on a JEOL Accu TOF 4G instrument. All the reagents were of analytical grade or freshly prepared before use in Schemes 1 and 2.

Synthesis of Key Pyrimidine Intermediates. Synthesis of Intermediates a1-a3. To a solution of 60% NaH (12.0 g, 0.300 mol) in THF (100 mL), a mix solution of ethyl 2-fluoropropanoate (20.0 g, 0.167 mol) and ethyl acetate (22.0 g, 0.250 mol) was added dropwise for 30 min. The mixture was stirred for 5 h at 30 °C and monitored with TLC. The reaction was quenched by 1 mol/L HCl. Ethyl acetate (EA) was extracted and dried by MgSO₄, giving

colorless oil **a1**³⁰ (21.1 g, yield 78.3%). The other intermediates **a2** ($R_2 = (CH_3)_2CH$, colorless oil, yield 76.9%) and **a3** ($R_2 = CHF_2$, colorless oil, yield 65.7%) were synthesized using the same method.

Synthesis of Intermediates b1-b3. To a solution of 30% NaOCH₃ (23.3 g, 0.129 mol) in CH₃OH (100 mL), formamidine acetate (6.42 g, 0.0617 mol) was added in batches for 30 min. Then, ethyl 4-fluoro-3-oxopentanoate (10.0 g, 0.0617 mol) was added dropwise. The mixture was stirred for further 24 h. The reaction was quenched by concentrated HCl to pH = 3–4. EA was extracted and dried by MgSO₄, giving white solid $b1^{31}$ (8.60 g, m.p. 155–156 °C, yield 99.0%). The other intermediates b2 ((R₂ = CH₃)₂CH, white solid, m.p. 161–162 °C, yield 85.5%) and b3 (R₂ = CHF₂, white solid, m.p. 150–151 °C, yield 80.3%) were synthesized using the same method.

Synthesis of Intermediates c1-c3. To a 100 mL round flask, intermediate b1 (4.30 g, 30.3 mmol) and NBS (6.40 g, 36.0 mmol) were dissolved in CH₃CN (50 mL). The mixture was stirred at room temperature for 8 h. Pure $c1^{32}$ was produced by rapid column chromatography (white solid, m.p. 93–94 °C, yield 98.1%). The other intermediates c2 (($R_2 = CH_3$)₂CH, yellow solid, m.p. 95–96

Scheme 2. Synthetic Route of Title Pyrimidinamine Compounds



°C, yield 80.5%) and c3 ($R_2 = CHF_2$, yellow solid, m.p. 86–87 °C, yield 95.6%) were synthesized using the same method.

Synthesis of Intermediates c4–c6. To a 100 mL round flask, intermediate b1 (4.30 g, 30.3 mmol) and NCS (6.80 g, 50.9 mmol) were dissolved in CH₃CN (50 mL). The mixture was stirred at room temperature for 8 h. Pure c4³² was obtained after rapid column chromatography (yellow solid, m.p. 83–84 °C, yield 75.6%). The other intermediates c5 (($R_2 = CH_3$)₂CH, yellow solid, m.p. 81–82 °C, yield 65.5%) and c6 ($R_2 = CHF_2$, yellow solid, m.p. 75–76 °C, yield 77.7%) were synthesized using the same method.

Synthesis of Intermediates d1-d8. To a 100 mL round flask, the intermediate c1 (6.50 g, 29.4 mmol) and POCl₃ (30 mL) were refluxed at 90 °C for 3 h. The reaction was quenched by H₂O and adjusted to neutral by saturated sodium bicarbonate solution. EA was extracted and dried by MgSO₄, giving a white solid $d1^{33}$ (6.00 g, colorless oil, yield 85.0%). The other intermediates d2 (R₂ = (CH₃)₂CH, R₃ = Br, colorless oil, yield 56.5%), d3 (R₂ = CHF₂, R₃ = Br, colorless oil, yield 37.6%), d4 (R₂ = CH₃CHF, R₃ = Cl, colorless oil, yield 55.6%), d5 (R₂ = (CH₃)₂CH, R₃ = Cl, colorless oil, yield 67.5%), d6 (R₂ = CHF₂, R₃ = Cl, colorless oil, yield 67.5%), d6 (R₂ = CHF₂, R₃ = Cl, colorless oil, yield 27.7%), d7 (R₂ = CH₃CHF, R₃ = H, colorless oil, yield 47.5%), and d8 (R₂ = CHF₂, R₃ = H, colorless oil, yield 65.5%) were synthesized using the same method.

Synthesis of Target Compounds. Synthesis of Intermediates 1a-1e. To a solution of p-methylbenzonitrile (35.0 g, 299 mmol) and K₂CO₃ (51.8 g, 375 mmol) in anhydrous methanol (300 mL), a solution of hydroxylamine hydrochloride (41.7 g, 600 mmol) in MeOH (90 mL) and H₂O (45 mL) was added dropwise at room temperature for 1 h and then heated to 80 °C for 5.5 h. The mixture was monitored by TLC. Then, methanol was evaporated, water (100 mL) and ethyl acetate (200 mL) were added, and the organic layer was extracted by ethyl acetate (100 mL \times 3), then dried, and recrystallized with ethyl acetate to obtain 1a (39.2 g,³⁴ white sticky, yield 87.1%). 1b (starting material 2-fluoro-4-methylbenzonitrile, white sticky, yield 85.0%), 1c(starting material 3-fluoro-4-methylbenzonitrile, white sticky, yield 86.2%), 1d (starting material 2,3difluoro-4-methylbenzonitrile, white sticky, yield 84.5%), and 1e (starting material 6-methylnicotinonitrile, white sticky, yield 84.5%) were synthesized using the same method.

Synthesis of Intermediates 2a-2e. To a solution of 1a (39.2 g, 261 mmol) in THF (400 mL), trifluoroacetic anhydride (82.3 g, 392 mmol) was added dropwise at 0 °C and then heated to 20 °C for 3 h. The mixture was monitored with TLC. The reaction was quenched by saturated sodium bicarbonate solution. EA was extracted and dried by MgSO₄, giving white solid $2a^{35}$ (44.7 g, colorless oil, yield 75.2%). 2b (starting material 2-fluoro-4-methylbenzonitrile, white solid, m.p. 60–

61 °C, yield 85.5%), **2c** (starting material 3-fluoro-4-methylbenzonitrile, white solid, m.p. 63–64 °C, yield 86.8%), **2d** (starting material 2,3-difluoro-4-methylbenzonitrile, brown solid, m.p. 70–71 °C, yield 84.2%), and **2e** (starting material 6-methylnicotinonitrile, colorless oil, yield 80.2%) were synthesized using the same method.

Synthesis of Intermediates 3a-3e. To a solution of 2a (44.7 g, 196 mmol) and NBS (36.2 g, 203 mmol) in CCl₄ (400 mL), AIBN (3.20 g, 19.5 mmol) was added dropwise at 65 °C and further stirred for 10 h. The mixture was detected by TLC. The reaction was quenched by saturated sodium bicarbonate solution. CH₂Cl₂ was extracted, dried by MgSO₄, and purified by column chromatography, giving white solid $3a^{35}$ (41.9 g, white solid, m.p. 60–61 °C, yield 70.5%). **3b** (starting material 2-fluoro-4-methylbenzonitrile, colorless oil, yield 68.8%), **1c** (starting material 3-fluoro-4-methylbenzonitrile, white solid, m.p. 70–71 °C, yield 64.7%), **1d** (starting material 2,3-difluoro-4-methylbenzonitrile, brown solid, m.p. 70–71 °C, yield 65.5%), and **1e**(starting material 6-methylnicotinonitrile, white solid, m.p. 64–65 °C, yield 65.3%) were synthesized using the same method.

Synthesis of Intermediates 4a–4e. To a solution of NaH (6.54 g, 273 mmol) in THF (400 mL), $(Boc)_2NH$ (35.6 g, 164 mmol) was added dropwise at room temperature. After further stirring for 30 min, the intermediate 3a (41.9 g, 136 mmol) was added. The mixture was further stirred for 12 h. Then, the reaction was quenched by H₂O. EA was extracted and dried by MgSO₄ to give crude intermediate 4a³⁶ (60.5 g), which was directly used in the next step without purification. Intermediates 4b, 4c, 4d, and 4e were synthesized using the same method.

Synthesis of Intermediates 5a-5e. Crude 4a (60.5 g) was added into a 1000 mL three-port flask, and the prepared HCl gas was passed into the three-port flask for 3 h under ice bath conditions. Then, the mixture was stirred at room temperature for 12 h. After adding MTBE, the solid was precipitated and then filtered. After drying, the gray solid $5a^{36}$ (30.5 g) was obtained (m.p. 240–241 °C, yield 80.1%). **Sb** (starting material 2-fluoro-4-methylbenzonitrile, white solid, m.p. 244–245 °C, yield 78.1%), **Sc** (starting material 3-fluoro-4methylbenzonitrile, white solid, m.p. 243–244 °C, yield 78.1%), **Sd** (starting material 2,3-difluoro-4-methylbenzonitrile, white solid, m.p. 251-252 °C, yield 75.1%), and **5e** (starting material 6-methylnicotinonitrile, white solid, m.p. 250–251 °C, yield 60.1%) were synthesized using the same method.

Synthesis of Target Pyrimidinamine Derivatives U1–U29. The key intermediates of **5** were synthesized using substituted 4methylbenzonitrile or substituted 6-methylnicotinonitrile as starting materials via five steps according to the reported references. Then, the intermediate **5** (0.500 mmol), substituted 4-chloropyrimidine (**d1**–

d8, 0.600 mmol), and *i*-Pr₂EtN (1.25 mmol) were dissolved in *n*-BuOH (10 mL), and the mixture was refluxed for 8 h. After the reaction was completed, the solvent was removed and purified by column chromatography, and a white solid was obtained (Table 1).

Table 1. Substituents of Compou	nds	sυ	1 - U29
---------------------------------	-----	----	---------

no.	\mathbb{R}^1	\mathbb{R}^2	R ³	Z
U1	Н	$(CH_3)_2CH$	Cl	С
U2	Н	$(CH_3)_2CH$	Br	С
U3	Н	CH ₃ CHF	Br	С
U4	Н	CH ₃ CHF	Cl	С
U5	Н	CH ₃ CHF	Н	С
U6	2-F	CH ₃ CHF	Н	С
U7	2-F	CH ₃ CHF	Cl	С
U8	2-F	CH ₃ CHF	Br	С
U9	3-F	CH ₃ CHF	Br	С
U10	3-F	CH ₃ CHF	Cl	С
U11	Н	CH ₃ CHF	Br	Ν
U12	Н	CH ₃ CHF	Cl	Ν
U13	2,3-diF	CH ₃ CHF	Cl	С
U14	2,3-diF	CH ₃ CHF	Br	С
U15	Н	CHF ₂	Br	С
U16	Н	CHF ₂	Cl	С
U17	Н	CHF ₂	Н	С
U18	2-F	CHF ₂	Br	С
U19	2-F	CHF ₂	Cl	С
U20	2-F	CHF ₂	Н	С
U21	Н	CHF ₂	Br	Ν
U22	Н	CHF ₂	Cl	Ν
U23	Н	CHF ₂	Н	Ν
U24	3-F	CHF ₂	Br	С
U25	3-F	CHF ₂	Cl	С
U26	3-F	CHF ₂	Н	С
U27	2,3-diF	CHF ₂	Cl	С
U28	2,3-diF	CHF ₂	Br	С
U29	2,3-diF	CHF ₂	Н	С

5-Chloro-6-isopropyl-N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)pyrimidin-4-amine (**U1**). White solid, m.p. 90–91 °C, yield 53.0%; ¹H NMR (CDCl₃, 600 MHz) δ: 1.26 (d, *J* = 7.2 Hz, 6H, -CH₃), 3.40–3.46 (m, 1H, -CH), 4.82 (d, *J* = 6.0 Hz, 2H, -CH₂), 5.77–5.85 (m, 1H, -NH), 7.50 (d, *J* = 7.8 Hz, 2H, Ar-H), 8.09 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.49 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 20.5, 31.4, 44.7, 111.9, 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 124.1, 128.1 (d, ²*J*_{C-F} = 4.2 Hz), 143.0, 155.5, 157.6, 165.9, 168.3, 168.9. HRMS *m*/*z* (ESI): Calculated for C₁₇H₁₅ClF₃N₅O ([M + H]⁺): 398.0990, found 398.0999.

5-Bromo-6-isopropyl-N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)pyrimidin-4-amine (**U2**). White solid, m.p. 117–118 °C, yield 57.0%; ¹H NMR (CDCl₃, 600 MHz) δ: 1.26 (d, *J* = 6.6 Hz, 6H, -CH₃), 3.40–3.46 (m, 1H, -CH), 4.82 (d, *J* = 6.0 Hz, 2H, -CH₂), 5.92–5.99 (m, 1H, -NH), 7.49 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.10 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.50 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 20.6, 33.8, 45.0, 104.0, 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 124.1, 128.1 (d, ²*J*_{C-F} = 2.1 Hz), 143.0, 156.1, 158.4, 165.9, 168.9, 169.9. HRMS *m*/*z* (ESI): Calculated for C₁₇H₁₅BrF₃N₅O ([M + H]⁺): 442.0485, found 442.0488.

5-Bromo-6-(1-fluoroethyl)-N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)pyrimidin-4-amine (**U3**). White solid, m.p. 62–63 °C, yield 52.0%; ¹H NMR (CDCl₃, 600 MHz) δ: 1.69 (dd, *J* = 24.0 Hz, 6.0 Hz, 3H, -CH₃), 4.84 (d, *J* = 6.0 Hz, 2H, -CH₂), 5.84–5.88 (m, 1H, -CH), 5.98–6.06 (m, 1H, -NH), 7.49 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.10 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.56 (s, H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 19.2 (d, *J*_{C-F} = 24.3 Hz, -CHFCH₃), 45.0, 87.8, 89.0, 102.6, 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 124.3, 128.2 (d, ²*J*_{C-F} = 4.4 Hz), 142.5, 156.8, 158.6, 161.8, 166.7, 168.8. HRMS *m*/z pubs.acs.org/JAFC

Article

(ESI): Calculated for $C_{16}H_{12}BrF_4N_5O$ ([M + H]⁺): 446.0234, found 442.0444.

5-*Chloro-6*-(1-fluoroethyl)-*N*-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)pyrimidin-4-amine (**U4**). White solid, m.p. 55–56 °C, yield 55.3%; ¹H NMR (CDCl₃, 600 MHz) δ: 1.69 (dd, *J* = 24.0 Hz, 6.6 Hz, 3H, -CH₃), 4.84 (d, *J* = 6.0 Hz, 2H, -CH₂), 5.85–5.90 (m, 1H, –CH), 5.93–5.99 (m, 1H, -NH), 7.49 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.10 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.57 (s, H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 19.2 (d, *J*_{C-F} = 24.3 Hz, -CHFCH₃), 44.8, 86.2, 87.4, 111.4, 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 124.3, 128.2 (d, ²*J*_{C-F} = 4.4 Hz), 142.5, 156.0, 158.0, 159.9, 165.7, 168.8. HRMS *m*/*z* (ESI): Calculated for C₁₆H₁₂CIF₄N₅O ([M + H]⁺): 402.0739, found 402.0740.

6-(1-Fluoroethyl)-N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)pyrimidin-4-amine (**U5**). White solid, m.p. 100–101 °C, yield 51.5%; ¹H NMR (CDCl₃, 600 MHz) δ: 1.62 (dd, *J* = 24.6 Hz, 6.0 Hz, 3H, -CH₃), 4.69 (s, 2H, -CH₂), 5.38–5.52 (m, 1H, -CH), 6.53 (s, 1H, Pyrimidine-H), 7.48 (d, *J* = 7.8 Hz, 2H, Ar-H), 8.09 (d, *J* = 7.8 Hz, 2H, Ar-H), 8.49 (s, H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 20.9 (d, *J*_{C-F} = 24.3 Hz, -CHFCH₃), 44.9, 89.6, 90.8, 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 124.3, 128.2 (d, ²*J*_{C-F} = 31.8 Hz), 142.5, 156.0, 158.0, 162.8, 165.9, 168.8. HRMS *m*/*z* (ESI): Calculated for C₁₆H₁₃F₄N₅O ([M + H]⁺): 368.1129, found 368.1130.

N-(2-*F*luoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)-6-(1-fluoroethyl)pyrimidin-4-amine (**U6**). White solid, m.p. 98–99 °C, yield 50.7%; ¹H NMR (CDCl₃, 600 MHz) δ : 1.63 (dd, *J* = 24.0 Hz, 6.0 Hz, 3H, -CH₃), 4.75 (d, *J* = 6.0 Hz, 2H, -CH₂), 5.65–5.75 (m, 1H, -CH), 5.88–5.93 (m, 1H, -NH), 6.45 (s, 1H, Pyrimidine-H), 7.46 (t, *J* = 7.8 Hz, 1H, Ar-H), 7.67 (dd, *J* = 10.2 Hz, 1.2 Hz, 1H, Ar-H), 7.72 (dd, *J* = 7.8 Hz, 1.2 Hz, 1H, Ar-H), 8.48 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ : 20.9 (d, *J*_{C-F} = 24.2 Hz, -CHFCH₃), 44.5, 87.8, 89.0, 101.5, 112.4, 115.3 (d, *J*_{C-F} = 21.3 Hz, Ar-F), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 123.4, 131.4 (d, ²*J*_{C-F} = 31.8 Hz), 157.8, 157.5, 160.3, 161.9, 165.9, 168.1. HRMS *m*/*z* (ESI): Calculated for C₁₆H₁₂F₅N₅O ([M + H]⁺): 386.1035, found 368.1130.

5-Chloro-N-(2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3yl)benzyl)-6-(1-fluoroethyl)pyrimidin-4-amine (**U7**). White solid, m.p. 54–55 °C, yield 53.1%; ¹H NMR (CDCl₃, 600 MHz) δ: 1.66 (dd, *J* = 24.0 Hz, 6.0 Hz, 3H, -CH₃), 4.87 (d, *J* = 6.0 Hz, 2H, -CH₂), 5.84–5.95 (m, 1H, -CH), 5.98–5.99 (m, 1H, -NH), 7.54 (t, *J* = 7.8 Hz, 1H, Ar-H), 7.83 (dd, *J* = 10.2 Hz, 1.2 Hz, 1H, Ar-H), 7.88 (dd, *J* = 7.8 Hz, 1.2 Hz, 1H, Ar-H), 8.55 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 19.0 (d, *J*_{C-F} = 24.2 Hz, -CHFCH₃), 39.0, 86.2, 87.3, 101.5, 111.5, 114.8 (d, *J*_{C-F} = 21.3 Hz, Ar-F), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 123.6, 131.4 (d, ²*J*_{C-F} = 31.8 Hz), 155.9, 157.9, 160.3, 161.9, 165.9, 168.1. HRMS *m*/*z* (ESI): Calculated for C₁₆H₁₁ClF₅N₅O ([M + H]⁺): 420.0645, found 420.0645.

5-Bromo-N-(2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3yl)benzyl)-6-(1-fluoroethyl)pyrimidin-4-amine (**U8**). White solid, m.p. 58–59 °C, yield 59.5%; ¹H NMR (CDCl₃, 600 MHz) δ: 1.66 (dd, *J* = 24.0 Hz, 6.0 Hz, 3H, -CH₃), 4.87 (d, *J* = 6.0 Hz, 2H, -CH₂), 5.82–5.93 (m, 1H, -CH), 6.05–6.06 (m, 1H, -NH), 7.53 (t, *J* = 7.8 Hz, 1H, Ar-H), 7.83 (dd, *J* = 10.2 Hz, 1.2 Hz, 1H, Ar-H), 7.88 (dd, *J* = 7.8 Hz, 1.2 Hz, 1H, Ar-H), 8.55 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 19.3 (d, *J*_{C-F} = 24.2 Hz, -CHFCH₃), 39.3, 87.8, 89.0, 102.5, 114.8 (d, *J*_{C-F} = 21.3 Hz, Ar-F), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 123.7, 126.1, 129.5, 130.8 (d, ²*J*_{C-F} = 31.8 Hz), 156.7, 158.6, 160.3, 161.9, 168.1. HRMS *m*/*z* (ESI): Calculated for C₁₆H₁₁BrF₅N₅O ([M + H]⁺): 464.0140, found 464.0140.

5-Bromo-N-(3-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3yl)benzyl)-6-(1-fluoroethyl)pyrimidin-4-amine (**U9**). White solid, m.p. 87–88 °C, yield 58.0%; ¹H NMR (CDCl₃, 600 MHz) δ: 1.69 (dd, *J* = 24.0 Hz, 6.6 Hz, 3H, -CH₃), 4.85 (t, *J* = 6.0 Hz, 2H, -CH₂), 5.84–5.97 (m, 1H, -CH), 6.06–6.11 (m, 1H, -NH), 7.25 (d, *J* = 10.8 Hz, 1H, Ar-H), 7.29 (d, *J* = 8.4 Hz, 1H, Ar-H), 8.07 (t, *J* = 7.2 Hz, 1H, Ar-H), 8.56 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 19.2 (d, *J*_{C-F} = 24.2 Hz, -CHFCH₃), 44.5, 87.8, 89.0, 102.5, 112.4, 115.7 (d, *J*_{C-F} = 21.3 Hz, Ar-F), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 123.4, 131.4 (d, ²*J*_{C-F} = 31.8 Hz), 145.3, 156.7, 158.5, 160.1,

162.0, 166.8. HRMS m/z (ESI): Calculated for $C_{16}H_{11}BrF_5N_5O$ ([M + H]⁺): 464.0140, found 464.0138.

5-Chloro-N-(3-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3yl)benzyl)-6-(1-fluoroethyl)pyrimidin-4-amine (**U10**). White solid, m.p. 83–84 °C, yield 51.5%; ¹H NMR (CDCl₃, 600 MHz) δ: 1.68 (dd, *J* = 24.0 Hz, 6.6 Hz, 3H, -CH₃), 4.84 (t, *J* = 6.0 Hz, 2H, -CH₂), 5.86–5.97 (m, 1H, -CH), 6.02 (t, *J* = 6.0 Hz, 1H, -NH), 7.24 (d, *J* = 10.8 Hz, 1H, Ar-H), 7.28 (d, *J* = 8.4 Hz, 1H, Ar-H), 8.06 (t, *J* = 7.2 Hz, 1H, Ar-H), 8.54 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 19.2 (d, *J*_{C-F} = 24.2 Hz, -CHFCH₃), 44.2, 86.2, 87.3, 111.5, 112.5, 115.6 (d, *J*_{C-F} = 21.3 Hz, Ar-F), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 123.5, 131.2 (d, ²*J*_{C-F} = 31.8 Hz), 145.3, 155.9, 157.9, 160.1, 161.8, 165.8. HRMS *m*/*z* (ESI): Calculated for C₁₆H₁₁ClF₅N₅O ([M + H]⁺): 420.0645, found 420.0640.

5-Bromo-6-(1-fluoroethyl)-N-((5-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)methyl)pyrimidin-4-amine (**U11**). White solid, m.p. 132–133 °C, yield 52.3%; ¹H NMR (CDCl₃, 600 MHz) δ: 1.66 (dd, *J* = 24.0 Hz, 6.0 Hz, 3H, -CH₃), 4.89 (t, *J* = 4.8 Hz, 2H, -CH₂), 5.85–5.96 (m, 1H, -CH), 7.03 (s, 1H, -NH), 7.48 (d, *J* = 8.4 Hz, 1H, Py-H), 8.37 (dd, *J* = 8.4 Hz, 2.4 Hz, 1H, Py-H), 8.55 (s, 1H, Py-H), 9.32 (d, *J* = 1.8 Hz, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 19.4 (d, *J*_{C-F} = 24.3 Hz, -CHFCH₃), 45.2, 87.8, 88.9, 102.7, 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 120.3, 122.1, 135.7 (d, ²*J*_{C-F} = 31.8 Hz), 148.3, 156.7, 158.4, 159.9, 161.7, 167.1. HRMS *m*/*z* (ESI): Calculated for C₁₅H₁₁BrF₄N₆O ([M + H]⁺): 447.0187, found 447.0186.

5-Chloro-6-(1-fluoroethyl)-N-((5-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)methyl)pyrimidin-4-amine (**U12**). White solid, m.p. 125–126 °C, yield 53.3%; ¹H NMR (CDCl₃, 600 MHz) δ: 1.66 (dd, *J* = 24.0 Hz, 6.0 Hz, 3H, -CH₃), 4.90 (t, *J* = 4.8 Hz, 2H, -CH₂), 5.86–5.97 (m, 1H, -CH), 6.95 (s, 1H, -NH), 7.48 (d, *J* = 8.4 Hz, 1H, Py-H), 8.37 (dd, *J* = 8.4 Hz, 2.4 Hz, 1H, Py-H), 8.55 (s, 1H, Py-H), 9.31 (d, *J* = 1.8 Hz, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 19.1 (d, *J*_{C-F} = 24.3 Hz, -CHFCH₃), 45.9, 86.1, 87.3, 111.7, 116.7 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 120.3, 122.1, 135.7 (d, ²*J*_{C-F} = 31.8 Hz), 148.3, 155.9, 157.8, 159.9, 166.1, 167.1. HRMS *m*/*z* (ESI): Calculated for C₁₅H₁₁ClF₄N₆O ([M + H]⁺): 403.0692, found 403.0692.

5-*Chloro-N-(2,3-difluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)-6-(1-fluoroethyl)pyrimidin-4-amine (U13).* White solid, m.p. 120–121 °C, yield 57.0%; ¹H NMR (CDCl₃, 600 MHz) δ : 1.67 (dd, *J* = 24.0 Hz, 6.6 Hz, 3H, -CH₃), 4.90 (d, *J* = 6.6 Hz, 2H, -CH₂), 5.84–5.96 (m, 1H, -CH), 6.00–6.04 (m, 1H, -NH), 7.32 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.82 (t, *J* = 6.6 Hz, 1H, Ar-H), 8.56 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ : 19.2 (d, *J*_{C-F} = 24.2 Hz, -CHFCH₃), 38.8, 86.2, 87.3, 111.6, 114.5 (d, *J*_{C-F} = 21.3 Hz, Ar-F), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 124.9 (d, *J*_{C-F} = 4.05 Hz, Ar-F), 131.8 (d, ²*J*_{C-F} = 31.8 Hz), 148.2, 150.3, 155.9, 157.8, 160.2, 165.6, 165.9. HRMS *m/z* (ESI): Calculated for C₁₆H₁₀ClF₆N₅O ([M + H]⁺): 438.0551, found 438.0551.

5-Bromo-N-(2,3-difluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)-6-(1-fluoroethyl)pyrimidin-4-amine (**U14**). White solid, m.p. 128–129 °C, yield 58.6%; ¹H NMR (CDCl₃, 600 MHz) δ : 1.67 (dd, *J* = 24.0 Hz, 6.6 Hz, 3H, -CH₃), 4.90 (d, *J* = 6.6 Hz, 2H, -CH₂), 5.83–5.96 (m, 1H, -CH), 6.00–6.04 (m, 1H, -NH), 7.32 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.82 (t, *J* = 6.6 Hz, 1H, Ar-H), 8.56 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ : 19.3 (d, *J*_{C-F} = 24.2 Hz, -CHFCH₃), 39.1, 87.8, 89.0, 102.5, 112.4, 114.5 (d, *J*_{C-F} = 21.3 Hz, Ar-F), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 124.9 (d, *J*_{C-F} = 4.05 Hz, Ar-F), 131.4 (d, ²*J*_{C-F} = 31.8 Hz), 145.3, 150.0, 156.7, 158.6, 161.9, 165.3. HRMS *m*/z (ESI): Calculated for C₁₆H₁₀BrF₆N₅O ([M + H]⁺): 482.0046, found 482.0047.

5-Bromo-6-(difluoromethyl)-N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)pyrimidin-4-amine (**U15**). White solid, m.p. 95 -96 °C, yield 52.3%; ¹H NMR (CDCl₃, 600 MHz) δ : 4.86 (d, *J* = 5.4 Hz, 2H, -CH₂), 6.12–6.19 (m, 1H, -NH), 6.74 (t, *J* = 53.4 Hz, 1H, -CHF₂), 7.49 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.11 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.59 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ : 45.1, 102.7, 112.3 (t, *J*_{C-F} = 240.0 Hz, -CHF₂), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 124.4, 128.2 (d, ²*J*_{C-F} = 7.8 Hz), 142.0, 154.5, 156.8, 159.0, 165.7, 168.9. HRMS m/z (ESI): Calculated for $C_{15}H_9BrF_5N_5O$ ([M + H]⁺): 449.9983, found 449.9993.

5-*C*hloro-6-(*difluoromethyl*)-*N*-(4-(5-(*trifluoromethyl*)-1,2,4-oxa*diazol-3-yl*)*benzyl*)*pyrimidin-4-amine* (**U16**). White solid, m.p. 87– 88 °C, yield 51.3%; ¹H NMR (CDCl₃, 600 MHz) δ : 4.86 (d, *J* = 6.0 Hz, 2H, -CH₂), 6.05–6.10 (m, 1H, -NH), 6.74 (t, *J* = 53.4 Hz, 1H, -CHF₂), 7.49 (d, *J* = 8.4 Hz, 1H, Ar-H), 8.11 (d, *J* = 7.8 Hz, 2H, Ar-H), 8.59 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ : 44.9, 109.9, 111.5 (t, *J*_{C-F} = 240.0 Hz, -CHF₂), 113.1, 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 124.4, 128.2 (d, ²*J*_{C-F} = 7.8 Hz), 142.0, 152.6, 156.1, 158.4, 166.0, 168.8. HRMS *m*/*z* (ESI): Calculated for C₁₅H₉ClF₅N₅O ([M + H]⁺): 406.0489, found 406.0492.

6-(Difluoromethyl)-N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3yl)benzyl)pyrimidin-4-amine (**U17**). White solid, m.p. 120–121 °C, yield 58.4%; ¹H NMR (CDCl₃, 600 MHz) δ: 4.73 (s, 2H, -CH₂), 6.72–5.77 (m, 1H, -NH), 6.41 (t, *J* = 53.4 Hz, 1H, -CHF₂), 6.66 (s, 1H, Pyrimidine-H), 7.48 (d, 2H, *J* = 8.4 Hz, Ar-H), 8.11 (d, 2H, *J* = 8.4 Hz, Ar-H), 8.61 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 44.9, 110.8, 112.4 (t, *J*_{C-F} = 240.0 Hz, -CHF₂), 114.0, 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 124.4, 128.2 (d, ²*J*_{C-F} = 7.8 Hz), 142.0, 155.5, 157.6, 158.8, 166.0, 168.8. HRMS *m*/*z* (ESI): Calculated for C₁₅H₁₀F₅N₅O ([M + H]⁺): 372.0878, found 372.0878.

5-Bromo-6-(difluoromethyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)pyrimidin-4-amine (**U18**). White solid, m.p. 93–94 °C, yield 53.2%; ¹H NMR (CDCl₃, 600 MHz) δ: 4.89 (d, J = 6.0 Hz, 2H, -CH₂), 6.16–6.26 (m, 1H, -NH), 6.72 (t, J = 53.4 Hz, 1H, -CHF₂), 7.55 (t, J = 7.8 Hz, 1H, Ar-H), 7.85 (d, J = 9.6 Hz, 1H, Ar-H), 7.89 (d, J = 8.4 Hz, 1H, Ar-H), 8.59 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 39.4, 102.8, 110.7, 112.3 (t, $J_{C-F} =$ 240.0 Hz, -CHF₂), 114.8 (d, $J_{C-F} = 24.1$ Hz, Ar-F), 116.5 (q, $J_{C-F} =$ 272.1 Hz, -CF₃), 123.7, 126.3, 129.0, 130.8 (d, ² $J_{C-F} = 7.8$ Hz), 142.0, 155.5, 157.6, 161.9, 168.0. HRMS m/z (ESI): Calculated for C₁₅H₈BrF₆N₅O ([M + H]⁺): 467.9889, found 467.9887.

5-*Chloro-6*-(*difluoromethyl*)-*N*-(2-*fluoro*-4-(5-(*trifluoromethyl*)-1,2,4-oxadiazol-3-yl)benzyl)pyrimidin-4-amine (**U19**). White solid, m.p. 85–86 °C, yield 52.3%; ¹H NMR (CDCl₃, 600 MHz) δ: 4.90 (d, J = 6.0 Hz, 2H, -CH₂), 6.10–6.16 (m, 1H, -NH), 6.73 (t, J = 53.4 Hz, 1H, -CHF₂), 7.55 (t, J = 7.8 Hz, 1H, Ar-H), 7.85 (dd, J = 10.2 Hz, 1.2 Hz, 1H, Ar-H), 7.90 (dd, J = 8.4 Hz, 1.8 Hz, 1H, Ar-H), 8.58 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 39.2, 102.8, 109.8, 111.4, 114.8 (t, $J_{C-F} = 240.0$ Hz, -CHF₂), 115.0 (d, $J_{C-F} = 24.1$ Hz, -CHF₂), 116.5 (q, $J_{C-F} = 272.1$ Hz, -CF₃), 126.3, 129.1, 130.9 (d, ² $_{J_{C-F}} = 7.8$ Hz), 152.7, 156.0, 158.4, 160.3, 161.9, 168.0. HRMS *m*/*z* (ESI): Calculated for C₁₅H₈ClF₆N₅O ([M + H]⁺): 424.0394, found 424.0387.

6-(Difluoromethyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)pyrimidin-4-amine (**U20**). White solid, m.p. 115– 116 °C, yield 53.5%; ¹H NMR (CDCl₃, 600 MHz) δ: 4.78 (s, 2H, -CH₂), 5.60–5.75 (m, 1H, -NH), 6.41 (t, *J* = 53.4 Hz, 1H, -CHF₂), 6.68 (s, 1H, Pyrimidine-H), 7.54 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.84 (d, *J* = 10.2 Hz, 1H, Ar-H), 7.89 (d, *J* = 7.8 Hz, 1H, Ar-H), 8.64 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 39.1, 109.8, 111.4, 112.3 (t, *J*_{C-F} = 240.0 Hz, -CHF₂), 115.0 (d, *J*_{C-F} = 24.1 Hz, -CHF₂), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 123.7, 129.0, 128.2 (d, ²*J*_{C-F} = 7.8 Hz), 142.0, 155.5, 157.6, 161.9, 168.0. HRMS *m*/*z* (ESI): Calculated for C₁₅H₉F₆N₅O ([M + H]⁺): 390.0784, found 390.0784.

5-Bromo-6-(difluoromethyl)-N-((5-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)methyl)pyrimidin-4-amine (**U21**). White solid, m.p. 148–149 °C, yield 55.4%; ¹H NMR (CDCl₃, 600 MHz) δ: 4.92 (d, *J* = 4.8 Hz, 2H, -CH₂), 6.77 (t, *J* = 53.4 Hz, 1H, -CHF₂), 7.50 (d, *J* = 8.4 Hz, 1H, Py-H), 8.40–8.42 (m, 1H, Py-H), 8.60 (s, 1H, Pyrimidine-H), 9.35 (d, *J* = 1.8 Hz, 1H, Py-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 46.1, 103.1, 112.3 (t, *J*_{C-F} = 240.0 Hz, -CHF₂), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 120.4, 122.2, 135.7, 148.2, 154.0, 156.8, 159.3 (d, ²*J*_{C-F} = 73.1 Hz), 161.9, 167.1. HRMS *m*/*z* (ESI): Calculated for C₁₄H₈BrF₅N₆O ([M + H]⁺): 450.9936, found 450.9945.

5-Chloro-6-(difluoromethyl)-N-((5-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)methyl)pyrimidin-4-amine (**U22**). White solid, m.p. 130–131 °C, yield 56.1%; ¹H NMR (CDCl₃, 600 MHz) δ: 4.93 (d, *J* = 4.8 Hz, 2H, -CH₂), 6.77 (t, *J* = 53.4 Hz, 1H, -CHF₂), 7.16–7.22 (m, 1H, -NH), 7.51 (d, *J* = 8.4 Hz, 1H, Py-H), 8.41 (dd, 1H, *J* = 8.4 Hz, 2.4 Hz, Py-H), 8.59 (s, 1H, Pyrimidine-H), 9.34 (d, *J* = 1.2 Hz, 1H, Py-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 45.8, 109.7, 112.3 (t, *J*_{C-F} = 240.0 Hz, -CHF₂), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 120.4, 122.2, 135.7, 148.2, 152.4, 156.1, 158.2, 159.3 (d, ²*J*_{C-F} = 73.1 Hz), 161.9, 167.1. HRMS *m*/*z* (ESI): Calculated for C₁₅H₈ClF₆N₅O ([M + H]⁺): 450.9936, found 450.9945.

6-(Difluoromethyl)-N-((5-(5-(trifluoromethyl)-1,2,4-oxadiazol-3yl)pyridin-2-yl)methyl)pyrimidin-4-amine (**U23**). White solid, m.p. 170–171 °C, yield 50.7%; ¹H NMR (CDCl₃, 600 MHz) δ: 4.92 (d, J = 4.8 Hz, 2H, -CH₂), 6.77 (t, J = 53.4 Hz, 1H, -CHF₂), 7.16–7.22 (m, 1H, -NH), 7.05 (s, 1H, Pyrimidine-H), 7.51 (d, J = 8.4 Hz, 1H, Py-H), 8.41 (dd, 1H, J = 8.4 Hz, 2.4 Hz, Py-H), 8.59 (s, 1H, Pyrimidine-H), 9.34 (d, J = 1.2 Hz, 1H, Py-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 45.7, 109.7, 112.3 (t, J_{C-F} = 240.0 Hz, -CHF₂), 116.5 (q, J_{C-F} = 272.1 Hz, -CF₃), 120.4, 122.2, 135.7, 148.2, 152.4, 156.8, 158.2, 159.3 (d, ²J_{C-F} = 73.1 Hz), 161.9, 167.1. HRMS m/z (ESI): Calculated for C₁₅H₉F₆N₅O ([M + H]⁺): 390.0784, found 390.0784.

5-Bromo-6-(difluoromethyl)-N-(3-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)pyrimidin-4-amine (**U24**). White solid, m.p. 110–111 °C, yield 56.3%; ¹H NMR (CDCl₃, 600 MHz) δ : 4.86 (d, *J* = 6.0 Hz, 2H, -CH₂), 6.19–6.26 (m, 1H, -NH), 6.74 (t, *J* = 53.4 Hz, 1H, -CHF₂), 7.23–7.28 (m, 1H, Ar-H), 7.29 (d, 1H, *J* = 7.8 Hz, Ar-H), 8.08 (t, 1H, *J* = 7.8 Hz, Ar-H), 8.58 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ : 44.6, 102.7, 110.7, 112.3 (t, *J*_{C-F} = 240.0 Hz, -CHF₂), 115.8 (d, *J*_{C-F} = 24.1 Hz, Ar-F), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 123.5(d, ²*J*_{C-F} = 7.8 Hz), 131.3, 144.7, 154.6, 156.8, 159.0, 160.0, 161.9, 165.7. HRMS *m*/*z* (ESI): Calculated for C₁₅H₈BrF₆N₅O ([M + H]⁺): 467.9889, found 467.9889.

5-Chloro-6-(difluoromethyl)-N-(3-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)pyrimidin-4-amine (**U25**). White solid, m.p. 95–96 °C, yield 55.0%; ¹H NMR (CDCl₃, 600 MHz) δ: 4.87 (d, J = 6.0 Hz, 2H, -CH₂), 6.11–6.18 (m, 1H, -NH), 6.75 (t, J = 53.4 Hz, 1H, -CHF₂), 7.26 (d, J = 9.6 Hz, 1H, Ar-H), 7.29 (d, 1H, J = 8.4 Hz, Ar-H), 8.08 (t, 1H, J = 7.8 Hz, Ar-H), 8.58 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ: 44.3, 102.7, 109.9, 111.5 (t, $J_{C-F} =$ 240.0 Hz, -CHF₂), 115.8 (d, $J_{C-F} = 24.15$ Hz, Ar-F), 116.5 (q, $J_{C-F} =$ 272.1 Hz, -CF₃), 123.7, 131.2 (d, ² $J_{C-F} = 7.8$ Hz), 144.8, 152.8, 156.0, 158.4, 160.0, 161.9, 165.7. HRMS m/z (ESI): Calculated for C₁₅H₈ClF₆N₅O ([M + H]⁺): 424.0394, found 424.0400.

6-(Difluoromethyl)-N-(3-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)pyrimidin-4-amine (**U26**). White solid, m.p. 120– 121 °C, yield 53.2%; ¹H NMR (CDCl₃, 600 MHz) δ : 4.76 (s, 2H, -CH₂), 5.45–6.87 (m, 1H, -NH), 6.42 (t, *J* = 53.4 Hz, 1H, -CHF₂), 6.68 (s, 1H, Pyrimidine-H), 7.25 (d, 1H, *J* = 10.8 Hz, Ar-H), 7.29 (d, 1H, *J* = 8.4 Hz, Ar-H), 8.08 (t, 1H, *J* = 7.2 Hz, Ar-H), 8.65 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ : 44.3, 110.8, 112.3 (t, *J*_{C-F} = 240.0 Hz, -CHF₂), 115.0(d, *J*_{C-F} = 24.15 Hz, Ar-F), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 123.7, 131.3 (d, ²*J*_{C-F} = 7.8 Hz), 144.8, 152.8, 156.0, 158.4, 160.0, 161.9, 165.7. HRMS *m*/z (ESI): Calculated for C₁₅H₉F₆N₅O ([M + H]⁺): 390.0784, found 390.0784.

5-*Chloro-N-(2,3-difluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)-6-(difluoromethyl)pyrimidin-4-amine* (**U27**). White solid, m.p. 128–129 °C, yield 58.0%; ¹H NMR (CDCl₃, 600 MHz) δ : 4.93 (d, *J* = 6.0 Hz, 2H, -CH₂), 6.13–6.19 (m, 1H, -NH), 6.73 (t, *J* = 53.4 Hz, 1H, -CHF₂), 7.33 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.83 (t, 1H, *J* = 6.6 Hz, Ar-H), 8.58 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ : 38.8, 110.8, 112.3 (t, *J*_{C-F} = 240.0 Hz, -CHF₂), 115.0 (d, *J*_{C-F} = 24.15 Hz, Ar-F), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 124.9 (d, *J*_{C-F} = 4.05 Hz, Ar-F), 128.2 (d, ²*J*_{C-F} = 7.8 Hz), 129.0, 142.0, 144.8, 152.8, 155.5, 157.6, 161.9, 166.7. HRMS *m/z* (ESI): Calculated for C₁₅H₇ClF₇N₅O ([M + H]⁺): 442.0300, found 442.0300.

5-Bromo-N-(2,3-difluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)-6-(difluoromethyl)pyrimidin-4-amine (**U28**). White solid, m.p. 131–132 °C, yield 58.2%; ¹H NMR (CDCl₃, 600 MHz) δ : 4.93 (d, *J* = 6.0 Hz, 2H, -CH₂), 6.21–6.29 (m, 1H, -NH), 6.72 (t, *J* = 53.4 Hz, 1H, -CHF₂), 7.32 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.83 (t, 1H, *J* = 6.6 Hz, Ar-H), 8.58 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ : 38.8, 110.8, 112.3 (t, *J*_{C-F} = 240.0 Hz, -CHF₂), 115.0 (d, *J*_{C-F} Article

= 24.15 Hz, Ar-F), 116.5 (q, J_{C-F} = 272.1 Hz, -CF₃), 124.9 (d, J_{C-F} = 4.05 Hz, Ar-F), 128.2 (d, ${}^2J_{C-F}$ = 7.8 Hz), 129.0, 142.0, 144.8, 152.8, 155.5, 157.6, 161.9, 166.7. HRMS m/z (ESI): Calculated for C₁sH₇BrF₇N₅O ([M + H]⁺): 485.9795, found 485.9795.

N-(2,3-*D*ifluoro-4-(5-(*trifluoromethyl*)-1,2,4-oxadiazol-3-yl)benzyl)-6-(difluoromethyl)pyrimidin-4-amine (**U29**). White solid, m.p. 170−171 °C, yield 55.3%; ¹H NMR (CDCl₃, 600 MHz) δ : 4.83 (s, 2H, -CH₂), 5.58−5.84 (m, 1H, -NH), 6.42 (t, *J* = 53.4 Hz, 1H, -CHF₂), 6.70 (s, 1H, Pyrimidine-H), 7.32 (t, 1H, *J* = 6.6 Hz, Ar-H), 7.29 (t, 1H, *J* = 6.6 Hz, Ar-H), 8.65 (s, 1H, Pyrimidine-H). ¹³C NMR (CDCl₃, 150 MHz) δ : 38.8, 110.8, 112.3 (t, *J*_{C-F} = 240.0 Hz, -CHF₂), 115.0 (d, *J*_{C-F} = 24.15 Hz, Ar-F), 116.5 (q, *J*_{C-F} = 272.1 Hz, -CF₃), 124.9 (d, *J*_{C-F} = 4.05 Hz, Ar-F), 128.2 (d, ²*J*_{C-F} = 7.8 Hz), 129.0, 142.0, 144.8, 152.8, 155.5, 157.6, 161.9, 166.7. HRMS *m*/z (ESI): Calculated for C₁₅H₇BrF₇N₅O ([M + H]⁺): 485.9795, found 485.9795.

Bioassay for the Compounds U1–U29. The insecticidal activities of compounds U1–U29 against *Mythimna separata, Aphis medicagini,* and *Tetranychus cinnabarinus* were evaluated by previously published methods.^{3,37}

Insecticidal Activity. *M. separata.* Corn (*Zea mays*) leaves were fully infiltrated in the sample solution, then dried, placed in a 20 cmdiameter Petri dish with third instar larvae, covered, and placed in the observation room. Results were determined after 72 h. The test was repeated four times.

A. medicagini. The foliar contact activities of compounds U1– U29 and flufenerim against *A.* medicagini were tested. Stock solutions of compounds U1–U29 were prepared in DMF at a concentration of $500 \ \mu g \ mL^{-1}$ and then diluted to 100, 20, 4, 0.8, and 0.16 $\ \mu g \ mL^{-1}$ with water containing Tween-20. Fresh shoots of broad bean (*Vicia faba*) with 100 *A.* medicagini were dipped in the above solutions with different concentrations for 5 s, then the excess fluid was removed, and they were kept in the conditioned room for normal cultivation. Mortality was evaluated by the number of live larvae in the treated bottles relative to that in the untreated controls after 24 h. Controls were performed under the same conditions. Each test was performed in triplicate.

T. cinnabarinus. Each of compounds U1-U29 was dissolved in CH_3COCH_3 and then diluted with water containing Tween-20 to 500 or 100 mg/L. Fresh broad bean (*V. faba*) leaves infested with 100 adult *T. cinnabarinus* were dipped into the test solution and swirled for 3 s. Then, broad bean (*V. faba*) leaf was placed in a tube (10 cm inner diameter) lined with a piece of filter paper. The acaricidal activity was evaluated 4 days after treatment and repeated four times. Zero percent indicates no activity, and 100% indicates a total kill.

Greenhouse *In Vivo* **Fungicidal Evaluation.** Fungicidal activities of compounds U1–U29 against *Pseudoperonospora cubensis* were tested with on potted cucumber in the greenhouse according to our previous work.^{38,39} Concentrations of the positive control (azoxystrobin) and the compounds U1–U29 were 50, 100, and 200 μ g/mL. The fungi *P. cubensis* was inoculated when the cucumber was at the two-seed leaf stage. After inoculation, the plants were cultured in a climate chamber for 10 days, and the relative control efficacy was calculated by the following equation:

relative control efficacy(%) = $(CK - PT)/CK \times 100\%$

where CK is the average disease index during the blank assay and PT is the average disease index after treatment during testing. All experiments were replicated three times.

Acetylcholine Esterase (AChE) Activity In Vivo from A. medicagini. Stock solutions of compounds U7, U8, and positive control flufenerim were prepared in DMF at 10 μ g mL⁻¹ with water containing Tween-20. When the potted broad bean seedlings grew to a height of 4–5 cm, the adult aphids were inoculated on the broad bean seedlings and then the stock solution was sprayed. The adult aphids were collected and homogenized after 2 days, and then the enzyme activity test was performed with an acetylcholin esterase kit. The enzyme activity assay was performed according to the method reported by Ellman et al.⁴⁰

pubs.acs.org/JAFC

Article

Table 2. Insecticidal Activity of Sy	nthesized Compounds agains	t M. separata and T. cin	nabarinus (mg/L) ^a

	M. separata			T. cinne	abarinus	
no.	500	100	20	4	500	100
U1	0	-	-	-	0	-
U2	0	-	-	-	0	-
U3	100 ± 0.0	80.3 ± 5.0	0	-	100 ± 0.0	100 ± 0.0
U4	100 ± 0.0	80.2 ± 3.1	0	-	95.2 ± 2.3	0
U5	0	-	-	-	0	-
U6	100 ± 0.0	30.3 ± 6.3	0	0	0	-
U7	100 ± 0.0	100 ± 0.0	79.8 ± 2.0	80.3 ± 7.0	90.1 ± 4.1	40.5 ± 5.0
U8	100 ± 0.0	100 ± 0.0	80.3 ± 1.3	60.2 ± 5.0	100 ± 0.0	30.4 ± 3.1
U9	70.3 ± 6.1	-	-	-	0	-
U10	100 ± 0.0	100 ± 0.0	0	0	0	-
U11	69.9 ± 4.2	-	-	-	0	-
U12	70.3 ± 5.0	-	-	-	0	-
U13	100 ± 0.0	100 ± 0.0	100 ± 0.0	0	0	-
U14	100 ± 0.0	100 ± 0.0	50.0 ± 10.0	0	0	-
U15	80.0 ± 2.0	0	0	0	0	-
U16	60.4 ± 6.1	-	-	-	0	-
U17	70.4 ± 8.2	-	-	-	0	-
U18	20.3 ± 10.1	-	-	-	0	-
U19	30.4 ± 7.0	-	-	-	80.0 ± 5.0	0
U20	20.0 ± 2.0	-	-	-	0	-
U21	0	-	-	-	0	-
U22	100 ± 0.0	0	0	0	0	-
U23	80.4 ± 3.0	0	0	0	0	-
U24	70.3 ± 5.2	-	-	-	0	-
U25	60.5 ± 4.5	-	-	-	0	-
U26	0	-	-	-	0	-
U27	100 ± 0.0	0	0	0	0	-
U28	0	-	-	-	0	-
U29	60.3 ± 5.0	-	-	-	0	-
flufenerim	100	100	100	70.0 ± 6.0	100	100
СК	0	0	0	0	0	0
^{<i>a</i>} Note: "-" is not te	sted.					

Molecular Docking. The structure of AChE (PDB ID: 10DC) was downloaded from protein data bank (PDB). The protein crystal structure AChE and the small molecule **U7**, **U8**, and flufenerim were prepared by standard methods using the discovery studio 2.5. After molecular docking, the best binding mode was selected according to the results of docking energy.⁴¹

Density Functional Theory (DFT-B3LYP) Analysis. According to the insecticidal and fungicidal results, flufenerim and highly active compound U7 were drawn in Gaussview 5.0 and then were optimized using DFT-B3LYP/6-31G methods according to our previous work.⁴²

RESULTS AND DISCUSSION

Synthesis and Spectra. The synthetic route of pyrimidin-4-amine derivatives is illustrated in Scheme 2. There are many references on natural products and synthetic compounds about the pyrimidine derivatives. Many classic pyrimidine synthetic methods were reported, such as Pinner synthesis, Remfry-Hull synthesis, Bredereck synthesis, Beginelli synthesis, and so on. In this work, the pyrimidine ring was synthesized (Pinner synthesis) using 1,3-diketone and amidine as reaction materials. For the final target compounds, if R_3 is Cl or Br, the compounds can be synthesized easily under Et_3N conditions. When R_3 is H, the yield is lower. If the base Et_3N is changed to DIPEA, the yield is increased but still lower than when R_3 is Cl or Br.

All the pyrimidine-4-amine derivatives were confirmed and characterized by ¹H NMR, ¹³C NMR, and HRMS. In the ¹H

NMR spectra of these pyrimidines, the difluoromethyl proton signals of the compounds **U15–U29** can be found around 6.5 ppm as a triple peak with the coupling constant 54 Hz. The appearance of signals at 8.5 ppm is assigned to pyrimidine. The NH peaks were found at 5.5-5.8 ppm as multipeaks. The single peak at 4.8 ppm was assigned as the NCH₂ peak. In the ¹³C NMR spectra of these pyrimidines, some carbons were split by the fluorine atom. Meanwhile, all of these pyrimidine compounds exhibited the M + H⁺ peak in the ESI-HRMS results.

Biological Activity. Insecticidal Activity. For M. separata, most of the title compounds possessed good activity (>70.0%)at 500 mg/L (Table 2). Among them, compounds U3, U4, U6, U7, U8, U10, U13, U14, U22, and U27 exhibited excellent activity (100%). At 100 mg/L, these compounds even possessed good activity (>80.0%), except for compounds U6, U22, and U27. Even at 20 mg/L, compounds U7, U8, and U13 still exhibited good activity (>80.0%), which is the same as the positive control flufenerim (100%). Compound U14 exhibited moderate activity (50.0%) against M. separata at 20 mg/L. With the concentration further reduced to 4 mg/L, the activity of compounds U13 and U14 disappeared, and only compounds U7 (80.3%) and U8 (60.2%) still exhibited good activity, which is still similar to the positive control flufenerim (70.0%) at 4 mg/L. The LC₅₀ values of compounds U7 (3.57 \pm 0.42 mg/L) and U8 (4.22 \pm 0.47 mg/L) are the same as that of the positive control flufenerim (3.14 \pm 0.73 mg/L) (Table 3).

Table 3. LC₅₀ of Compounds U7, U8, and Flufenerim against *M. separata*

compound	$LC_{50} (mg/L)$	regression equation	r
U7	3.57 ± 0.42	Y = 1.64X + 4.10	0.971
U8	4.22 ± 0.47	Y = 1.64X + 3.98	0.993
flufenerim	3.14 ± 0.73	Y = 0.94X + 4.50	0.968

For *T. cinnabarinus* (Table 2), it is just the opposite of the activity against *M. separata*. Most of the compounds exhibited no activity at 500 mg/L, except for compounds U3, U4, U7, and U8. These four compounds displayed excellent activity (>90.0%) at 500 mg/L. Compound U3 still exhibited good activity (100%) at 100 mg/L, which is similar to the positive control flufenerim (100%). However, the other three compounds U4, U7, and U8 exhibited moderate activity (<50.0%) at 100 mg/L.

For A. medicagini (Table 4), compounds U3, U4, U5, U6, U7, U8, U9, U10, U13, U14, U15, U16, U18, and U19 displayed good activity (>90.0%) at 500 ppm. Compounds U3, U4, U7, U8, U9, U10, and U19 still maintained excellent activity (100%) at 100 mg/L. Surprisingly, compounds U3,

Table 4. Insecticidal Activity against A. medicagini (mg/L)^a

U7, and U8 still possessed excellent activity (100%) at 20 mg/ L, which is still the same as the positive control flufenerim (100%). Notably, compounds U7 and U8 still exhibited excellent activity (100%) at 4 mg/L. When the concentration was reduced to 0.8 mg/L, the activity of compounds U7 (80.2%) and U8 (60.4%) was still good, which is a little weaker than that of the positive control flufenerim (100%). However, the two compounds still possessed good activity (>60.0%) at 0.16 mg/L, which is better than that of flufenerim (10.0%).

Fungicidal Activity against *P. cubensis In Vivo.* Most of the compounds (U1, U2, U3, U4, U7, U8, U10, U13, U15, U16, U24, U27, and U28) possessed good activity (>80.0%) against *P. cubensis* at 200 mg/L (Table 5), which is similar to the positive control azoxystrobin (95.0%). Compounds U1, U2, U3, U4, U7, and U8 were selected for further screening. Among them, compounds U3, U4, U7, and U8 exhibited a good control effect (>80.0%) at 100 mg/L, which is better than that of azoxystrobin (65.0%) at the same concentration. At 50 mg/L, U7 and U8 exhibited a good control effect (\sim 70.0%), which is better than that of azoxystrobin (54.0%). The EC₅₀ values (Table 6) were 24.94 ± 2.13, 30.79 ± 2.21, and 3.18 ± 0.21 mg/L for U7, U8, and azoxystrobin against *P. cubensis*, respectively.

Structure–Activity Relationship. Structure–activity relationship analysis indicated that both R_1 and R_2 are important

		e 1	•			
			A. me	dicagini		
no.	500	100	20	4	0.8	0.16
U1	0	-	-	-	-	-
U2	0	-	-	-	-	-
U3	100 ± 0.0	100 ± 0.0	100 ± 0.0	80.3 ± 3.2	0	0
U4	100 ± 0.0	100 ± 0.0	90.0 ± 4.1	89.9 ± 6.0	0	0
U5	90.3 ± 5.2	0	0	0	-	-
U6	90.1 ± 7.2	70.2 ± 3.0	30.3 ± 10.3	0	-	-
U7	100 ± 0.0	100 ± 0.0	100 ± 0.0	100 ± 0.0	80.2 ± 4.1	60.2 ± 5.0
U8	100 ± 0.0	100 ± 0.0	100 ± 0.0	100 ± 0.0	60.4 ± 2.0	60.3 ± 5.0
U9	90.2 ± 1.0	100 ± 0	40.4 ± 5.2	0	-	-
U10	100 ± 0	100 ± 0	80.0 ± 3.0	40.2 ± 4.2	0	-
U11	80.3 ± 5.0	0	0	0	-	-
U12	80.4 ± 5.2	79.7 ± 2.3	20.5 ± 1.0	0	-	-
U13	100 ± 0.0	90.2 ± 4.9	90.4 ± 2.0	60.1 ± 8.2	59.6 ± 4.4	-
U14	100 ± 0.0	70.3 ± 5.0	40.3 ± 7.9	0	-	-
U15	90.2 ± 6.2	40.1 ± 2.2	0	0	-	-
U16	100 ± 0.0	80.0 ± 4.0	0	0	-	-
U17	0	-	-	-	-	-
U18	100 ± 0.0	59.9 ± 4.0	0	0	-	-
U19	100 ± 0.0	100 ± 0.0	79.9 ± 5.1	70.2 ± 3.1	-	-
U20	80.2 ± 3.0	0	0	0	-	-
U21	0	-	-	-	-	-
U22	80.3 ± 6.2	0	0	0	-	-
U23	60.3 ± 5.3	-	-	-	-	-
U24	90.4 ± 2.9	30.1 ± 2.0	0	0	-	-
U25	0	-	-	-	-	-
U26	0	-	-	-	-	-
U27	0	-	-	-	-	-
U28	0	-	-	-	-	-
U29	0	-	-	-	-	-
flufenerim	100 ± 0.0	100 ± 0.0	100 ± 0.0	100 ± 0.0	100 ± 0.0	10.0 ± 5.0
СК	0	0	0	0	0	0

"Note:"-" is not tested.

Table 5. Control Effect of Title Compounds against P. cubensis $(\%)^a$

		P. cubensis	
no.	200 mg/L	100 mg/L	50 mg/L
U1	80.0 ± 8.1	5.1 ± 2.2	-
U2	100 ± 0.0	10.2 ± 3.0	-
U3	100 ± 0.0	80.2 ± 5.1	-
U4	100 ± 0.0	80.1 ± 9.9	-
U5	45.2 ± 8.1	-	-
U6	0	-	-
U7	100 ± 0.0	90.0 ± 5.0	70.2 ± 3.0
U8	100 ± 0.0	89.4 ± 2.3	67.4 ± 3.1
U9	50.0 ± 4.0	-	-
U10	90.1 ± 2.1	-	-
U11	59.8 ± 6.2	-	-
U12	29.9 ± 5.1	-	-
U13	90.2 ± 7.1	-	-
U14	60.1 ± 5.1	-	-
U15	100 ± 0.0	-	-
U16	80.3 ± 3.4	-	-
U17	20.2 ± 2.1	-	-
U18	69.8 ± 5.2	-	-
U19	100 ± 0.0	-	-
U20	70.1 ± 4.2	-	-
U21	10.3 ± 2.2	-	-
U22	30.2 ± 5.2	-	-
U23	0	-	-
U24	100 ± 0.0	-	-
U25	40.0 ± 4.0	-	-
U26	15.2 ± 2.9	-	-
U27	84.8 ± 5.2	-	-
U28	100 ± 0.0	-	-
U29	15.0 ± 3.0	-	-
azoxystrobin	90.0 ± 5.0	65.0 ± 3.0	54.0 ± 2.0
СК	0	0	0
Note: "-" is not t	ostad		

^aNote: "-" is not tested.

Table 6. EC_{50} of Compounds U7, U8, and Azoxystrobin against *P. cubensis*

compound	$EC_{50} (mg/L)$	regression equation	r
U7	24.94 ± 2.13	Y = 2.34X + 1.73	0.980
U8	30.79 ± 2.21	Y = 2.47X + 1.33	0.974
azoxystrobin	3.18 ± 0.21	Y = 2.92X + 3.53	0.983

for the activity. For the R_1 substitution, when R_1 is H or 2-F, the compounds displayed the best insecticidal and fungicidal activity. While with 2,3-diF substitution on the compounds, the activity decreased. The activity of 3-F substitution on the compounds gave the lowest activity. Hydrogen bonds may have formed between the halogen atom and the NH group (Figure 3). The intramolecular three-center hydrogen bond is



Figure 3. Intramolecular hydrogen bonds between the NH and halogen atoms.

pu	bs.a	cs.o	rg/	'JA	FC	

regarded as an efficient and reliable control for molecular conformation and influence for bioactivity. Therefore, the activity trend of R_1 is 2-F > H > 3-F > 2,3-diF. For the R_2 substitution, when R_2 is a CH₃CHF group, compounds always possessed excellent insecticidal and fungicidal activity (e.g., U3–U14). If the CH₃CHF group was replaced by CHF₂, the activity decreased. Furthermore, if the CH₃CHF group was changed to an iso-Pr group, the activity disappeared. The activity trends of R_2 is CH₃CHF > CHF₂ > (CH₃)₂CH. The halogen on the pyrimidine ring had no impact on the activity. For example, whether compounds had a Cl atom or Br atom on the pyrimidine ring, they still exhibited good insecticidal and fungicidal activity (e.g., U3, U4, U7, and U8). The activity trend of halogens is Cl > Br > H.

Mode of Action. Although IRAC did not report the mode of action of flufenerim, Ghanim⁹ and co-workers reported that the mode of action of flufenerim may target AChE, so compounds U7, U8, and the positive control flufenerim were selected as representative compounds to test their inhibitory activity against AChE in vivo. The enzyme activities of compounds U7, U8, and flufenerim are 0.215, 0.184, and 0.184 U/mg prot, respectively. The results that we obtained here showed that the compounds U7 and U8 may have the same mode of action as flufenerim. Further biochemical and genetic assays are in progress.

Molecular Docking of U7, U8, and Flufenerim. From the reference and bioassay, the compounds U7 and U8 may have the same mode of action as flufenerim (AChE inhibitors), so we conducted molecular modeling analysis of compounds U7, U8, and flufenerim with TcAChE. As shown in Figure 4, there were two $\pi - \pi$ interactions for compounds U7 and U8 between Trp84 and the 1,2,4-oxadiazole ring with distances of 4.5 and 4.6 Å, respectively. On the other hand, there was $\pi - \pi$ interaction between Tyr334 and the pyrimidine ring with distances of 5.2 Å (U8) or 4.8 Å (U8). Furthermore, there was a strong hydrogen bonding interaction (2.4 and 2.3 Å) between Tyr121 of TcAChE and NH in the compounds U7 and U8, respectively. For the positive control flufenerim, there were also two $\pi - \pi$ interactions between Trp84 and the pyrimidine ring with distances of 5.2 and 6.2 Å, respectively. It was also observed in many co-crystals of TcAChE with Tacrine.⁴³ Meanwhile, there was $\pi - \pi$ interaction between Tyr334 and the benzene ring with a distance of 5.3 Å. Furthermore, there were two strong hydrogen bonds existing between Tyr121 of TcAChE and the nitrogen atom of the pyrimidine ring and Asp72 of TcAChE and NH of flufenerim with distances of 2.6 and 2.2 Å, respectively.

DFT Calculation of High-Activity U7 and Flufenerim. Molecular total energy (MTE), frontier orbital energy (FMO), energy gap between the HOMO and LUMO, ClogP, and TPSA of high-activity compound U7 and flufenerim are calculated using the B3LYP method, and the results are listed in Table 7.

According to the FMO theory, LUMO and HOMO are the most important factors that affect the electron transition. LUMO can accept electrons, while HOMO can provide electrons. Hence, the frontier orbital energy, HOMO, LUMO, and energy gap can provide useful information about the biological mechanism. From Figure 5, the geometries of compound U7 and flufenerim contain two parts: the pyrimidine ring and substituted phenyl ring. The HOMO of the compound U7 is mainly located on the pyrimidine ring, while the LUMO of compound U7 is located on the phenyl



YR-121

Figure 4. Simulated binding modes of compounds U7, U8, and flufenerim with TcAChE.

YR-121

Table 7. Total Energy and Frontier Orbital Energy

energy	flufenerim	U7
$E_{\rm total}/{\rm Hartree}$	-1678.635	-1924.137
$E_{\rm HOMO}/{\rm Hartree}$	-0.232	-0.226
$E_{\rm LUMO}/{\rm Hartree}$	-0.033	-0.105
$\Delta E^{\rm a}/{ m Hartree}$	0.199	0.121
TPSA	47.1	76.7
CLogP	5.04	3.87

ring and 5-(trifluoromethyl)-1,2,4-oxadiazole ring. The electron transition occurs from the pyrimidine ring to 5-(trifluoromethyl)-1,2,4-oxadiazole ring via the phenyl ring. The energy gap is 0.121 Hartree. On the other hand, the HOMO of flufenerim is mainly located on the pyrimidine ring, phenyl ring, and NCH₂CH₂ bridge, and the LUMO of flufenerim is located on the pyrimidine ring. The electron transition is from the phenyl ring to the pyrimidine ring via the NCH₂CH₂ bridge, and the energy gap is 0.199 Hartree. From Figure 5, the electron transition orientation is opposed. The total energies of the compound U7 and flufenerim are different: compound U7 (-1924.137 Hartree) and lead compound flufenerim (-1678.635 Hartree).

Physiochemical properties of molecules play key roles in pesticide properties.⁴⁴ The topological polar surface areas (TPSA) were calculated from the website (http://www.molinspiration.com/cgi-bin/properties), and the octanol-water partition coefficients (ClogP) were calculated by Chemdraw. It is reported⁴⁵ that the ClogP value of insecticides is 4.00 ± 2.30 . The ClogP value of our positive control flufenerim is 5.04, which is higher than the average value of

ClogP for commercial insecticides. The ClogP value of optimized candidate compound U7 is 3.87, which is similar to that of commercial insecticides. From Table 7, the most suitable TPSA value may be around 50, and the TPSA of positive control flufenerim is 47.1, which was very close to 50. However, the TPSA of compound U7 is 76.7, which is much higher. Therefore, when designing more potent insecticidal compounds in the future, perhaps keeping the ClogP values of the designed compounds around 5.0 and maintaining TPSA values near 50 will improve insecticidal activity.

Molecular Electrostatic Potential (MEP) of Flufenerim and Compound U7. Knowing the molecular electrostatic potential, mainly the van der Waals (vdW) surface of a molecule, is critical for predicting intermolecular interactions,^{46,47} such as electrophilic and nucleophilic reactions, hydrogen bonding interactions, and molecular recognition processes. Besides the ESP surface, this model can help visualize charged regions (negative or positive) of a molecule in order to check the interactions between receptors and other compounds.⁴⁸ Hence, we selected flufenerim and the highly active compound U7 to conduct ESP analysis. As shown in Figure 6, the positive regions (blue) are the phenyl ring or alkyl group of U7 or flufenerim. The negative regions (red and yellow) mainly around the fluorine atom or the nitrogen atoms on the pyrimidine ring may play an important role between the compound and its pesticide target site receptor.

Toxicity. Acute oral toxicities were carried out at Zhejiang Changsanjiao Chemicals Safety Evaluation Co., Ltd. The compounds U7 and U8 were selected for testing according to the pesticide standard procedure. Unfortunately, the compounds U7 and U8 possessed high toxicity against rat (LD₅₀:



Figure 5. HOMO and LUMO of U7 and flufenerim.

Journal of Agricu	ultural and Food Chemistry			pubs.acs.org/JAFC	Article
-1.502+-2		4, 982+-2	-4.9574-2		4.987e-2

Figure 6. Molecular electrostatic potential (MEP) of flufenerim (left) and compound U7 (right).

oral, <500 mg/kg), while the positive control flufenerim has low toxicity. Their different toxicity may be attributable to the different $\pi - \pi$ interactions and different hydrogen bonds, which had the opposite docking mode between compound U7 or U8 and positive control flufenerim in the active site of AChE. Also, from the results of DFT calculations of compound U7 and flufenerim, the molecular total energy (MTE), energy gap between the HOMO and LUMO, ClogP, and TPSA of compound U7 and flufenerim are different. Hence, the docking results and DFT calculation results provided meaningful information to design potential low-toxic pyrimidin-4-amine insecticides. Further structure optimization is undergoing according to the molecular docking model and DFT calculation results, which will be reported in the near future.

AUTHOR INFORMATION

Corresponding Authors

Xing-Hai Liu – College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310014, China; orcid.org/0000-0003-1464-1426; Email: xhliu@ zjut.edu.cn

Ning-Jie Wu – Zhejiang Base of National Southern Pesticide Research Centre, Zhejiang Research Institute of Chemical Industry, Hangzhou 310023, China; Email: wuningjie@ sinochem.com

Authors

- Yong-Hui Wen College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310014, China; Zhejiang Base of National Southern Pesticide Research Centre, Zhejiang Research Institute of Chemical Industry, Hangzhou 310023, China
- Long Cheng College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310014, China; Zhejiang Base of National Southern Pesticide Research Centre, Zhejiang Research Institute of Chemical Industry, Hangzhou 310023, China
- **Tian-Ming Xu** Zhejiang Base of National Southern Pesticide Research Centre, Zhejiang Research Institute of Chemical Industry, Hangzhou 310023, China

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.jafc.1c00236

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was funded by Zhejiang Provincial Natural Science Foundation of China (no. LY19C140002) and by Research Fund of the Department of Education of Zhejiang Province (Y202043162). We thank Ji-Ping Yu and Jia-Hua Xing for evaluating insecticidal activity and fungicidal activity. We also thank Dr. Stephen O. Duke for language editing.

REFERENCES

(1) Guo, W.; Xing, Y.; Zhang, Q.; Xie, J.; Huang, D.; Gu, H.; He, P.; Zhou, M.; Xu, S.; Pang, X.; Liu, M.; Yi, Z.; Chen, Y. Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of N-Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth. J. Med. Chem. **2020**, 63, 676–695.

(2) Yang, J.; Guan, A.; Li, Z.; Zhang, P.; Liu, C. Design, Synthesis, and Structure-Activity Relationship of Novel Spiropyrimidinamines as Fungicides against Pseudoperonospora cubensis. *J. Agric. Food Chem.* **2020**, *68*, 6485–6492.

(3) Wu, N.; Cheng, L.; Wang, J.; Yu, J.; Xing, J.; Xu, T.; Wei, Y. Synthesis and Insecticidal Activity of Novel 4-Arylamino Pyrimidine Derivatives. *Chin. J. Org. Chem.* **2019**, *39*, 852–860.

(4) Zhang, N.; Huang, M. Z.; Liu, A. P.; Liu, M. H.; Li, L. Z.; Zhou, C. G.; Ren, Y. G.; Ou, X. M.; Long, C. Y.; Sun, J.; Dang, M. M.; Lan, Z. L. Design, synthesis, and insecticidal/acaricidal evaluation of novel pyrimidinamine derivatives containing phenyloxazole moiety. *Chem. Pap.* **2020**, *74*, 963–970.

(5) Mohana, K. N.; Mallesha, L. Synthesis and in vitro biological activity of N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinamine derivatives. *Bulg. Chem. Commun.* **2011**, *43*, 395–400.

(6) Wishka, D. G.; Graber, D. R.; Kopta, L. A.; Olmsted, R. A.; Friis, J. M.; Hosley, J. D.; Adams, W. J.; Seest, E. P.; Castle, T. M.; Dolak, L. A.; Keiser, B. J.; Yagi, Y.; Jeganathan, A.; Schlachter, S. T.; Murphy, M. J.; Cleek, G. J.; Nugent, R. A.; Poppe, S. M.; Swaney, S. M.; Han, F.; Watt, W.; White, W. L.; Poel, T.-J.; Thomas, R. C.; Voorman, R. L.; Stefanski, K. J.; Stehle, R. G.; Tarpley, W. G.; Morris, J. (-)-6-chloro-2-[(1-furo[2,3-c]pyridin-5-yl-ethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor. J. Med. Chem. **1998**, *41*, 1357–1360.

(7) Cuccia, S. J.; Wood, W. W.; Buckwalter, B. L.; Chiarello, J. F.; Fleming, L. B. Acaricidal and insecticidal substituted pyrimidines and a process for the preparation thereof. US 6,281,219, 1999.

(8) Guan, A.; Wang, M.; Yang, J.; Wang, L.; Xie, Y.; Lan, J.; Liu, C. Discovery of a New Fungicide Candidate through Lead Optimization of Pyrimidinamine Derivatives and Its Activity against Cucumber Downy Mildew. J. Agric. Food Chem. 2017, 65, 10829–10835.

(9) Ghanim, M.; Lebedev, G.; Kontsedalov, S.; Ishaaya, I. Flufenerim, a Novel Insecticide Acting on Diverse Insect Pests: Biological Mode of Action and Biochemical Aspects. *J. Agric. Food Chem.* **2011**, *59*, 2839–2844.

(10) Zhang, Y.; Shang, J.; Li, H.; Liu, H.; Song, H.; Wang, B.; Li, Z. Synthesis of novel N-pyridylpyrazole derivatives containing 1,2,4-

pubs.acs.org/JAFC

oxadiazole moiety via 1,3-dipolar cycloaddition and their structures and biological activities. *Chin. Chem. Lett.* **2020**, *31*, 1276–1280.

(11) Dai, H.; Ding, Y.; Du, X.; Yao, W.; Chen, Q.; Wang, X.; Zhong, S.; Cao, X.; Shi, Y. Synthesis and Biological Activities of Novel Pyrazole Oximes Containing Substituted Oxadiazole Moiety. *Chin. J. Org. Chem.* **2018**, *38*, 1755–1762.

(12) Ravinaik, B.; Ramachandran, D.; Basaveswara Rao, M. V. Design, Synthesis and Anticancer Evaluation of 1,2,4-Oxadiazole Bearing Isoxazole-Pyrazole Derivatives. *Lett. Org. Chem.* **2020**, *17*, 352–359.

(13) Mohammadi-Khanaposhtani, M.; Fahimi, K.; Karimpour-Razkenari, E.; Safavi, M.; Mahdavi, M.; Saeedi, M.; Akbarzadeh, T. Design, Synthesis and Cytotoxicity of Novel Coumarin-1,2,3-triazole-1,2,4-Oxadiazole Hybrids as Potent Anti-breast Cancer Agents. *Lett. Drug Des. Discov.* **2019**, *16*, 818–824.

(14) Yang, S.; Tian, X. Y.; Ma, T. Y.; Dai, L.; Ren, C. L.; Mei, J. C.; Liu, X. H.; Tan, C. X. Synthesis and Biological Activity of Benzamides Substituted with Pyridine-Linked 1,2,4-Oxadiazole. *Molecules* **2020**, 25, 3500.

(15) Bhargavi, M. V.; Shashikala, P.; Sumakanth, M.; Krishna, C. Synthesis, Molecular Docking, Analgesic, and Anti-Inflammatory Activities of New 1,2,4-Oxadiazolo-Sulfonamides. *Rus. J. Gen. Chem.* **2018**, *88*, 804–811.

(16) Cunha, F.; Nogueira, J.; de Aguiar, A. Synthesis and Antibacterial Evaluation of 3,5-Diaryl-1,2,4-oxadiazole Derivatives. *J. Braz. Chem. Soc.* **2018**, *29*, 2405–2416.

(17) Avanzo, R. E.; Padrón, J. M.; D'Accorso, N. B.; Fascio, M. L. Synthesis and in vitro antiproliferative activities of (5-ary1-1,2,4-oxadiazole-3-y1) methyl D-ribofuranosides. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 3674–3677.

(18) dos Santos, J. M.; Macedo, T. S.; Teixeira, H. M. P.; Moreira, D. R. M.; Challal, S.; Wolfender, J. L.; Queiroz, E. F.; Soares, M. B. P. Conjugation of N-acylhydrazone and 1,2,4-oxadiazole leads to the identification of active antimalarial agents. *Bioorg. Med. Chem.* **2016**, *24*, 5693–5701.

(19) Wieja, A.; Winter, C.; Rosenbaum, C.; Kremzow-Graw, D.; Roehl, F.; Rheinheimer, J.; Poonoth, M.; Terteryan, V.; Haden, E.; Escribano, C.A.; Achenbach, J. H.; Mentzel, T.; Wiebe, C. Use of substituted oxadiazoles for combating phytopathogenic fungi. WO 2,015,185,485, 2015.

(20) Wiebe, C.; Kretschmer, M.; Grammenos, W.; Eaxribano, C. A.; Quintero, P. M. A.; Craig, I. R.; Cambeis, E.; Grote, T.; Fehr, M.; Mentzel, T.; Mueller, B.; Winter, C.; Terteryan-Seiser, V.; Lohmann, J. K. Use of substituted oxadiazoles for combating phytopathogenic fungi. WO 2,017,076,739, 2017.

(21) Brunet, S.; Coqueron, P.; Desbordes, P.; Ducerf, S.; Dufoyr, J.; Goertz, A.; Hilt, E.; Mallinger, A.; Naud, S.; Rebstock, A.; Thomas, V. Use of 1,3,4-oxadiazole derivatives for controlling phytopathogenic fungi including Puccinia species, Uromyces species and rust disease pathogens. WO 2,020,127,974, 2020.

(22) Brunet, S.; Desbordes, P.; Ducerf, S.; Dufoyr, J.; Goertz, A.; Gourgues, M.; Hilt, E.; Naud, S.; Rebstock, A.; Thomas, V.; Vernay, A.; Villalba, F.; Gortz, A. New oxadiazole derivatives used to control unwanted phytopathogenic microorganisms i.e. phytopathogenic fungi causing rust diseases and protecting storage goods. WO 2,019,155,066, 2019.

(23) Quintero, P. M. A.; Terteryan-Seiser, V.; Grammenos, W.; Wiebe, C.; Montag, J.; Coquiller, M.; Neumann, T. Fungicidal mixture used to control phytopathogenic harmful fungi, comprises 3phenyl-5-trifluoromethyl-(1,2,4)oxadiazole compound and active agent of e.g. respiration inhibitors, sterol biosynthesis inhibitors, herbicides and insecticides. WO 2,019,115,511, 2019.

(24) Hoffman, T. J.; Stierli, D.; Pitterna, T.; Beaudegnies, R.; Rajan, R. New oxadiazole derivatives used as fungicides for controlling or preventing infestation of useful plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, preferably fungi, and for protecting plants. WO 2,019,097,054, 2019.

(25) Hoffman, T. J.; Stierli, D.; Pitterna, T.; Rajan, R. New oxadiazole derivatives used e.g. to control or prevent infestation of

useful plants by phytopathogenic microorganisms i.e. fungi for protecting technical materials e.g. wood and wood related technical products, and in food storage. WO 2,019,011,928, 2019.

(26) Matsuzaki, Y.; Nakano, T.; Inoue, T. Composition useful for controlling plant disease in agricultural lands such as fields, paddy fields, lawns, and orchards, comprises fungicidal compounds and oxadiazole compounds. WO 2,017,110,864, 2017.

(27) Shen, Z. H.; Sun, Z. H.; Becnel, J. J.; Estep, A.; Wedge, D. E.; Tan, C. X.; Weng, J. Q.; Han, L.; Liu, X. H. Synthesis and Mosquiticidal Activity of Novel Hydrazone Containing Pyrimidine Derivatives against Aedes aegypti. *Lett. Drug Des. Discov.* **2018**, *15*, 951–956.

(28) Liu, X. H.; Wang, Q.; Sun, Z. H.; Wedge, D. E.; Becnel, J. J.; Estep, A. S.; Tan, C. X.; Weng, J. Q. Synthesis and insecticidal activity of novel pyrimidine derivatives containing urea pharmacophore against Aedes aegypti. *Pest Manage. Sci.* **2017**, *73*, 953–959.

(29) Liu, X. H.; Tan, C. X.; Weng, J. Q. Phase transfer-catalyzed one-pot synthesis of some novel N-Pyrimidinyl-N'-Nicotinyl Thiourea derivatives. *Phosphorus, Sulfur Silicon Relat. Elem.* **2011**, *186*, 552–557.

(30) Ahlsten, N.; Bartoszewicz, A.; Agrawal, S.; Martin-Matute, B. A facile synthesis of α -fluoro ketones catalyzed by $[Cp*IrCl_2]_2$. Synthesis **2011**, *16*, 2600–2608.

(31) Yoshida, H.; Ohmori, K.; Fuse, K.; Morita, K.; Onduka, Y.; Yokota, N., 4-Fluoro-3-oxocarboxylic esters and process for producing the same. WO 9,931,044, 1999.

(32) Yoshida, H.; Ohmori, K.; Fuse, K.; Morita, K.; Onduka, Y.; Yokota, N., 6-(1-fluoroalkyl)-4-pyrimidones and processes for producing the same. WO 9,944,997, 1999.

(33) Grammenos, W.; Craig, I. R.; Boudet, N.; Mueller, B.; Dietz, J.; Lauterwasser, E. M. W.; Lohmann, J. K.; Montag, J., New substituted pyrimidine compounds, useful for combating phytopathogenic harmful fungi on various cultivated plants such as cereals e.g. wheat, rye, barley, triticale, oats or rice. WO 2,013,113,782, 2013.

(34) Maciel, L. G.; Oliveira, A. A.; Romão, T. P.; Leal, L. L.; Guido, R. V.; Silva-Filha, M. H. N.; dos Anjos, J. V.; Soares, T. A. Discovery of 1,2,4-oxadiazole derivatives as a novel class of noncompetitive inhibitors of 3-hydroxykynurenine transaminase (HKT) from *Aedes aegypti. Bioorg. Med. Chem.* **2020**, *28*, 115252.

(35) Bhujade, P. R.; Naik, M. N.; Kale, M. G.; Gade, V.; Vashishtha, T.; Autkar, S. S.; Garg, R., Klausener, A. G. M.; Dengale, R. A.; Aswale, P. D.; My, P., Novel oxadiazole compounds for controlling or prenenting phytopathogenic fungi. WO 2,020,208,509, 2020.

(36) Beaudegnies, R.; Hoffman, T. R.; Pouliot, M.; Stierli, D., Microbiocidal oxadiazole derivatives. WO 2,017,103,219, 2017.

(37) Zhong, L. K.; Kang, S. J.; Tan, C. X.; Weng, J. Q.; Xu, T. M.; Liu, X. H. Synthesis, acaricidal activities and docking study of novel acrylonitrile derivatives. *ARKIVOC* **2019**, *part vi*, 386–396.

(38) Shi, J. J.; Ren, G. H.; Wu, N. J.; Weng, J. Q.; Xu, T. M.; Liu, X. H.; Tan, C. X. Design, synthesis and insecticidal activities of novel anthranilic diamides containing polyfluoroalkyl pyrazole moiety. *Chin. Chem. Lett.* **2017**, *28*, 1727–1730.

(39) Liu, X. H.; Qiao, L.; Zhai, Z. W.; Cai, P. P.; Cantrell, C. L.; Tan, C. X.; Weng, J. Q.; Han, L.; Wu, H. K. Novel 4-Pyrazole Carboxamide Derivatives Containing Flexible Chain Motif: Design, Synthesis and Antifungal Activity. *Pest Manage. Sci.* **2019**, *75*, 2892–2900.

(40) Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem. Pharmacol.* **1961**, *7*, 88–95.

(41) Fu, Q.; Cai, P. P.; Cheng, L.; Zhong, L. K.; Tan, C. X.; Shen, Z. H.; Han, L.; Xu, T. M.; Liu, X. H. Synthesis and herbicidal activity of novel pyrazole aromatic ketone analogs as HPPD inhibitor. *Pest Manage. Sci.* **2020**, *76*, 868–879.

(42) Liu, X. H.; Fang, Y. M.; Xie, F.; Zhang, R. R.; Shen, Z. H.; Tan, C. X.; Weng, J. Q.; Xu, T. M.; Huang, H. Y. Synthesis and in vivo fungicidal activity of some new quinoline derivatives against rice blast. *Pest Manage. Sci.* **2017**, *73*, 1900–1907.

(43) Harel, M.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P. H.; Silman, I.; Sussman, J. L. Quaternary

ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. *Proc. Natl. Acad. Sci. U. S. A.* **1993**, *90*, 9031–9035.

(44) Liu, X.-H.; Yu, W.; Min, L.-J.; Wedge, D. E.; Tan, C. X.; Weng, J. Q.; Wu, H. K.; Cantrell, C. L.; Bajsa-Hischel, J.; Hua, X. W.; Duke, S. O. Synthesis and Pesticidal Activities of New Quinoxalines. *J. Agric. Food Chem.* **2020**, *68*, 7324–7332.

(45) Hao, G.; Dong, Q.; Yang, G. A Comparative study on the constitutive properties of marketed pesticides. *Mol. Inf.* **2011**, *30*, 614–622.

(46) Du, Q. S.; Wang, C. H.; Wang, Y. T.; Huang, R. B. Empirical and accurate method for the threedimensional electrostatic potential (EM-ESP) of biomolecules. *J. Phys. Chem. B.* **2010**, *114*, 4351–4357.

(47) Yan, Z.; Liu, A.; Ou, Y.; Li, J.; Yi, H.; Zhang, N.; Liu, M.; Huang, L.; Ren, J.; Liu, W.; Hu, A. Design, synthesis and fungicidal activity evaluation of novel pyrimidinamine derivatives containing phenyl-thiazole/oxazole moiety. *Bioorg. Med. Chem.* **2019**, *27*, 3218– 3228.

(48) Zhang, F.; Liu, B.; Liu, G.; Zhang, Y.; Wang, J.; Wang, S. Substructure-activity relationship studies on antibody recognition for phenylurea compounds using competitive immunoassay and computational chemistry. *Sci. Rep.* **2018**, *8*, 3131.